Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
The interaction between tumor-derived exosomes and stroma plays a crucial role in tumor progression. However, the mechanisms through which tumor cells influence stromal changes are not yet fully understood. In our study, through single-cell sequencing analysis of clear cell renal cell ...
During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic renal cell carcinoma.
Herein, we present a novel case of a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib who subsequently developed ...
Due to recent advances in ccRCC treatment, many options for therapy are available. There is a paucity of data on real-world treatment trends. Using ...
Scott Tykodi, MD, PhD, discusses data from CheckMate 214 for nivolumab plus ipilimumab vs sunitinib in favorable-risk advanced RCC.
Methods: Two ccRCC expression profiles were downloaded from Gene Expression Omnibus (GEO), and one dataset was gained from The Cancer Genome Atlas ( ...
Recent studies have identified a biological process called adherent-to-suspension transition (AST) as a key factor in promoting metastasis. The involvement of AST in the progression of clear cell renal cell carcinoma (ccRCC) remains largely unexplored. We comprehensively investigated the ...
There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were treated in the advanced setting.
During a live event, Guru P. Sonpavde, MD discussed first-line renal cell carcinoma regimens with varying efficacy and toxicity profiles.
During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ipilimumab plus nivolumab in non–clear cell renal cell carcinoma.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.